期刊文献+

盐酸维拉佐酮的合成工艺改进研究 被引量:1

Improvement of synthetic process of vilazodone hydrochloride
原文传递
导出
摘要 目的对盐酸维拉佐酮的合成工艺进行改进。方法以4-(4-乙酰基哌嗪-1-基)苯酚为起始原料,经Duff反应、取代、环化、脱保护、酰胺化得到关键中间体5-(1-哌嗪基)-苯并呋喃-2-甲酰胺,再与3-(4-氯丁酰基)-1H-吲哚-5-甲氰缩合、成盐得到盐酸维拉佐酮。结果合成了目标化合物盐酸维拉佐酮,并利用~1H-NMR、MS确证了结构,质量分数为99.8%,该路线的总收率为22.5%。结论该合成工艺原料廉价易得、操作简单,适于工业化生产。 Objective To improve the process for synthesis of vilazodone hydrochloride.Methods The key intermediate 5-(1- piperazinyl)benzofuran-2-carboxamide was prepared from 4-(4-acetylpiperazine-1-yl)phenol by Duff reaction, substitution, cyclization, deprotection, and amidation. Vilazodone hydrochloride was synthesized from 5-(1-piperazinyl)benzofuran-2-carboxamide and 3-(4-chlorobutyryl)-1H-indole-5-carbonitrile by substitution and salification.Results The target compound vilazodone hydrochloride was synthesized and characterized by1H-NMR and MS. The purity was 99.8%, and the total yield of this synthetic route was 22.5%. Conclusion The synthetic process with facile material and simple operation simplified method is applicable to industrial production.
出处 《现代药物与临床》 CAS 2017年第3期361-364,共4页 Drugs & Clinic
关键词 盐酸维拉佐酮 合成工艺 Duff反应 工业化生产 vilazodone hydrochloride synthetic process Duff reaction industrial production
  • 相关文献

参考文献4

二级参考文献30

  • 1KHAN A. Vilazodone, a novel dual-acting serotonergic antidepres- sant for managing major depression [ J ]. Expert Opin lnvestig Drugs, 2009,18 ( 11 ) : 1753 - 1764.
  • 2HOWLAND RH. Vilazodone: another novel atypical antidepres- sant drug[ J ] . J Psychosoc Nurs Ment Health Serv , 2011,49 ( 3 ) : 19 -22.
  • 3DAWSON LA, WATSON JM. Vilazodone: a 5-HT1A receptor ago- nist/serotonin transporter inhibitor for the treatment of affective disorders [ J ]. CNS Neurosci Ther ,2009 ,15 (2) : 107 - 117.
  • 4DE PAULIS T. Drug evaluation: vilazodone- a combined SSRI and 5-HT1A partial agonist for the treatment of depression [ J]. Drugs,2007,10 ( 3 ) : 193 - 201.
  • 5ROBERTS C, HAGAN JJ, BARTOSZYK GD, et al. Effect of vilazodonc on 5-HT efflux and re-uptake in the guinea-pig dorsal raphc nucleus [ J ]. Eur J Pharmacol,2005,517 ( 1 - 2 ) : 59 - 63.
  • 6HUGHES ZA, STARR KR, LANGMEAD C J, et al. Neurochemi- cal evaluation of the novel 5-HT1A receptor partial agonist/seroto- nin reuptake inhibitor, vilazodone [ J ]. Eur J Pharmacol, 2005, 510(1 -2) :49 -57.
  • 7Vilazodone [ EB/OL ]. [ 2011 - 05 - 20 ]. http ://www. accessda-ta. fda. gov/drugsatfda docs/label/20! 1/022567s0001b1. pdf.
  • 8RICKELS K, ATHANASIOU M, ROBINSON DS,et al. Evidenee for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-con- trolled trial[ J ]. J Clin Psychiatry, 2009,70 ( 3 ) : 326 - 333.
  • 9KHAN A, CUTLER AJ, KAJDASZ DK, et al. A randomized, double-blind, plaeebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder [J]. J Clin Psyehiatry,2011,72(4):441 -447.
  • 10Qian D Q,Heteroatom Chemistry,1997年,8卷,517页

共引文献49

同被引文献10

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部